Disc Medicine, Inc. (IRON) CMO discloses Rule 10b5-1 stock sales

Rhea-AI Filing Summary

Disc Medicine, Inc. reported that a company officer serving as Chief Medical Officer sold shares of common stock on 12/15/2025 in open-market transactions executed under a Rule 10b5-1 trading plan adopted on June 26, 2025.

The sales included 3,642 shares at a weighted average price of $90.6037 (with trades between $90.02 and $90.97), 9,151 shares at a weighted average price of $91.4353 (with trades between $91.03 and $91.99), and 300 shares at $92.23.

After these transactions, the reporting person directly beneficially owned 75,702 shares of Disc Medicine common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Savage William Jacob

(Last) (First) (Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/15/2025		S(1)		3,642	D	$90.6037(2)	85,153	D
Common Stock	12/15/2025		S(1)		9,151	D	$91.4353(3)	76,002	D
Common Stock	12/15/2025		S(1)		300	D	$92.23	75,702	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.02 to $90.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.03 to $91.99, inclusive.

	By: /s/ Rahul Khara, as Attorney-in-Fact	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock transactions did Disc Medicine (IRON) disclose in this filing?

The filing shows that the Chief Medical Officer sold 3,642, 9,151, and 300 shares of Disc Medicine common stock on 12/15/2025 in three separate transactions.

At what prices did the Disc Medicine Chief Medical Officer sell shares?

The officer sold shares at weighted average prices of $90.6037 (with trades from $90.02 to $90.97), $91.4353 (with trades from $91.03 to $91.99), and $92.23.

Was the Disc Medicine (IRON) insider sale made under a Rule 10b5-1 trading plan?

Yes. The transactions were effected under a Rule 10b5-1 trading plan that was adopted on June 26, 2025, as described in the footnotes.

How many Disc Medicine shares does the reporting person own after these sales?

Following the reported transactions, the reporting person directly beneficially owned 75,702 shares of Disc Medicine common stock.

What is the reporting person’s role at Disc Medicine (IRON)?

The reporting person is listed as an officer of Disc Medicine with the title Chief Medical Officer and is not marked as a director or 10% owner.

Were any derivative securities reported in this Disc Medicine insider filing?

The document includes a section for derivative securities, but it does not list any specific derivative security transactions in the provided table.

How were the share prices calculated for the reported Disc Medicine stock sales?

The prices in the table are weighted average prices; the filing notes that the shares were sold in multiple transactions within the stated price ranges for footnotes (2) and (3).